<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 253 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page252.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=253">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 253 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 253</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=253"><img src="../thumb/253.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>216 / 2020-04                                                            Genital System - 17.1.1
   REASONS FOR IMMEDIATE DISCONTINUATION: Occurrence for the   Indications: Fertil.contr.in women, cert.menstr. irreg.  is 7 days. Next patch needs to be applied on the next day follow.
   1st time of migraine headache. More frequent occurrence of unusually   (S3) TABS. H/18.8/10.  patch-free cycle even if there has been no bleed./bleed.not yet stop.
   severe headache. Sudden perception disorders (ie. disturbed vision,   825808-006: 28, R53,64  If change days are delay: at the start of any patch cycle (Wk One/Day
   hearing). 1st signs of thrombophlebitis or thromboembolic symptoms.   Dosage: 1 tab at same time dly commenc.1st day of menstr.cycle.  1): Apply first patch of new cycle as soon as rememb. Non-horm.con-
                                                                        st
   Onset of unexplained pain & tightness of chest. Pending operations   Contraindications, Side effects, Special precautions, Drug   tracept.to be used for 1  7 days of new cycle. In midd.of patch cycle
   (6 weeks before). Immobilisation (eg. after accidents). Onset of   interactions: See sect.head note.  (wk 2/Day 8 or Wk 3/Day 15) for 1 or 2 days up to 48 hrs: apply new
   jaundice/hepatitis or generalised pruritus. Increase in epileptic   patch immed. Next patch to be applied on usual ‘change day’. No
   seizures. Significant rise in BP. Known or suspected pregnancy. Sud-  DEPO-PROVERA 150, Pfizer [P/S]  addit. contracept.need. For more than 2 days (48 hrs or more): stop
   den upper abdominal pain.    Medroxyprogesterone acetate.  curr.contracept.cycle & start new 4 wk cycle immed. A non-horm.
   PEOPLE AT RISK: Cigarette smokers especially more than 15/day.   Indications: Inject.contracept.(ovulat.suppress.)  contracept. must be used for 1  consec.days of the new cycle. At
                                                                           st
   History of preeclamptic toxaemia. Women over 35 yrs. Continual   (S4) INJ E/21.8.2/114. 150 mg/ml.  the end of patch cycle (Wk 4/Day 22) patch should be remov. Next
   use for more than 5 years. Obesity. Hypertension. Diabetes. Hyper-  718440-005: 1x1 ml, R48,69  cycle should be start.on usual ‘change day’ which is day aft. Day 28.
                                                         st
                                                 st
   cholesterolaemia. Familial hyperlipoproteinaemia.   Dosage: 150 mg IMI 3 mnthly. Recomm.1  admin. given dur.1  5 days   No addit. contracept.reqd.
   SIDE EFFECTS: Breast disorders/pain; changes in libido; hepatitis;   after onset of menstrual period./ within 5 days post part.if not breast   Switch from an OC: begin on 1  day of withdraw. bleed.
                                                                            st
                                               th
   benign, malignant and unspecified neoplasms including breast   feed./ if exclus.breastfeed.at/aft.6  week post partum.  Aft.childbirth: If not breast feed.commenc.ther.no soon.than 4
   cancer, benign breast neoplasm, hepatic adenoma, cervical dys-  Contraindications: Undiagn.vag./urin.tract bleed./breast pathology,   wks.aft.deliver.
   plasia, focal nodular hyperplasia, fibroadenoma of breast, breast   thrombophlebit./hist. thereof., sev.liv.funct.impairm., bef.menarche  Aft abortion: Bef.20 wks.gestat Start immed. At/aft. 20 wks.ges-
   cyst; fluid retention; gall bladder disease; GI disorders including   Side effects: Signific.bone miner.density loss, hypersens.reacts.   tat: Start on day 21 post-abort/ on 1  day of spontan.menstruat.
                                                                              st
   abdominal pain, abdominal distension, colitis, pancreatitis; head-  eg.anaphylact./anaphylactoid reacts., angio-oed., suppress.adren.  whichever is 1 . st
   aches/migraine; Increase in disease of circulatory system (coronary   funct., menstr. bleed. chang., weight chang., vaginit., fluid retent.,   Contraindications, side effects, special precautions & drug
   thrombosis, cerebrovascular accidents and venous thrombosis); hot   Cushingoid sympts., decr.libido/anorgasm., CNS eff.incl.somnol.&   interactions: See sect. headnote.
   flushes; cardiac disorders including MI, tachycardia and palpitations;   convuls., hot flush., thrombo-embol.dis., abdom.pain/discomf., GI
   respiratory disorders including pulmonary embolism & dyspnoea; liver   disturbs., jaund., disturb liv.funct., rash, acne, alopec., hirsut., prurit.,   FEMODENE ED, Bayer [P/S]
   enlargement; dyslipidaemia; nervous system disorders including syn-  urticar., backache, musc./leg cramps, osteoporos.& relat.fractures, ar-  21 hormonal tabs: Gestodene 0,075 mg, ethinylestradiol 0,03 mg,
   cope, convulsion, paraesthesia, dizziness; weight changes; appetite   thralg., amenorrh. & anovulat., leucorrh., mastodyn., breast tendern.,   7 non-hormonal tabs.
   changes; psychiatric disorders including mood changes, depression,   dysmenorrh., galactorrh., chang.in cervic. eros.& secret., virilisat., fem-  Indications: Oral contracept.
   nervousness, anxiety, insomnia; nausea and vomiting;  musculoskel-  inisat., pelvic pain, asthen., fatig., pyrex.,inj.site.reacts., decr. gluc.tol.  (S3) TABS, W/21.8.2/98
   etal disorders including muscle spasms, extremity pain, myalgia and   Warnings and special precautions: Loss of BMD in adolesc./   825905-001: 28, R115,06
   back pain; eye disorders including retinal vascular thrombosis, visual   early adulthood & pre-menopaus. women theref.consid.risk/benef.   Dosage: 1 tab at same time dly.commenc.1st day of menstr.cycle.
   impairment, dry eyes, poor tolerance of contact  lenses; hypertension;   assessm., bone loss is &gt; with incr.durat.& compl. revers.may not be   Contra-indications, Side-effects, Special precautions, Drug
   reproductive system disorders including dysmenorrhoea, metrorrha-  poss., risk benef.analys.in women with osteoporot./osteoporos.  interactions: See sect. headnote.
   gia, spotting; abnormal withdrawal bleeding, prolonged  amenorrhoea   risk fact., adeq. Ca.& vit.D intake recomm., developm.of thrombo
   after discontinuation, ovarian cysts, supressed lactation; skin and   embol.S&S, ophthalm.eval.if vis.disturbs. exper., when treat. cert.  GINETTE, Cipla Medpro (Pty) Ltd
   subcutaneous tissue disorders including rash, skin pigmentation/  cancers cortic.-like activ. report. with the very high dos., progestat.  See Section 14.6
   discoloration, angioedema, eruthema nodosum, hisutism, sweating,   agent. dur. pregn.not recomm., diabet., poss.masks onset of climacter.,   IMPLANON NXT, MSD [P/S]
   acne, alopecia, urticarial, pruritus and erythema; UTIs; vaginal infec-  liv.dis./dysfunct., not recomm.for second. amenorrh./dysfunct.uter.  Etonogestrel
   tions/candidiasis/discharge; varicose  complaints; vertigo.  bleed., hypercalcaem., condit.affect.by fluid retent., Cushingoid   Indications: Contracept.
   SPECIAL PRECAUTIONS: Thorough history and examination before   sympts.in high dos., investig. abnorm. bleed., ment.depress.hist.,   (S4) IMPL. 34/18.8/0448. 68 mg/implant
   prescribing, and regular examination during use; history of depression;   consid.alternat.long term (&gt;2 yrs) birth control methods, menstr.cy-  718619-001: 1, R2 318,92
   past oligomenorrhoea or  amenorrhoea;  adequate precaution prior   cle disrupt., physic.examin.pts bef.treatm.with specif. ref.to breast   Dosage: For subdermal insert.under asept.condits. Can be left in
   to  and following elective surgery; alternative contraception must   & pelvic.organs as well as perform pap. smear, excl.organ.causes if   place for 3 yrs. Remov.no lat.than 3 yrs.aft.dat.of insert. Impl.can be
   be instituted if treatment is stopped;  during vomiting or diarrhoea   bleed.irreg., adeq. diagn.meas.indicat.for undiagn.vag.bleed., cert.  remov.at any time. Aft.remov.immed.insert.of anoth.impl.will result
   absorption may be diminished and require additional contraceptive   lab. endocr.& liv.funct.tests poss.affect., overall slight/ no incr.breast   in contin.contracept.protect.
   agents; may interfere with laboratory tests; decreased glucose   Ca risk, consid.not re-admin.meds if jaund. devel., no protect.against   Ref.to.prod.lit.for insert./remov.instructs.
   tolerance in diabetics therefore control must be carefully supervised;   HIV(AIDS) infects./ other STD’s  No preced.hormon.contracept.use in preced. cycle: Insert
   increased risk of congenital anomalies in  pregnancy; cardiovascular   Drug interactions: Bioavailabil.depress.by aminoglutethimide.,   betw.day 1-5 of menstr.cycle.
   problems related to smoking - women who take oral contraceptives   decr.serum oestrog.lev., ACTH & hydrocortis.bld.lev.poss.decr.  Chang.from combin.hormon.contracept.: Tablets: Insert on day
   should be advised not to smoke; careful observation  required if   follow.last activ.tab.of prev. comb. oral contracept/at latest on day
   patient have or have had the following conditions: breast nodules,   DIANE-35, Bayer (Pty) Ltd  follow.tab-free/placeb.tab.interv. Vag.Ring/transderm.patch: insert
   fibrocystic disease of the breast or abnormal mammogram, history   See Section 14.6  on day of remov./at latest when next applicat. due.
   of severe depression, varicose veins, sickle cell anaemia, diabetes,   DIVA 35, Unicorn Pharmaceuticals (Pty) Ltd  Chang.from progestag.-only contracept. method: Progesta-
   hypertension, high cholesterol, epilepsy, asthma, osteosclerosis,   See Section 14.6  gen-only pill: Switch on any day but within 24 h of last tab. Implant/
   multiple  sclerosis, porphyria, tetany, disturbed liver functions,
   gallstones, cardiovascular disease, kidney disease, chloasma, herpes   ESCAPELLE, Litha [P/S]  IUCD: Switch on day of remov. Inject.: Switch on day next inject.due.
                                                                         st
   of pregnancy. The worsening or  first appearance of any of these   Levonorgestrel  Follow.abort./miscarr: 1  trimest.: Insert within 5 days follow.abort./
                                                                  nd
   conditions may indicate that oral contraceptives should be stopped;   Indications: Emerg.contracept.within 72 hrs.of unprotect.sex.inter-  miscarr. 2  trimest.: Insert betw. 21-28 days follow.abort./miscarr.
                                                                            th
   discontinue in case of unexplained transient/partial/complete loss of   course/fail.of contracept. method.  Postpart.:Breastfeed. Insert.aft.4  postpart.week. Use barr.method
   vision, onset of blurred vison/diplopia, papilledema or retinal vascular   (S2) TABS, 41/21.8.2/0021  unt.7 days aft.insert. Not breastfeed.: Insert.betw.21-28 days postpart.
   lesions; avoid exposure to sun in case of chloasma gravidarum   710109-001: 1,50 mg, 1, R62,19  If deviat.from recomm.tim.of insert.use of barr. method unt.7 days
   history; presence of predisposing factors increasing risk of arterial/  Dosage: Take tab.no later than 72 hrs.aft. unprotect. sex.intercourse.   aft.insert.adv.
   venous thromboembolic diasease; present or recent hepatic disease;   Take another tab. immed. if vomit.occurs.within 3-4 hrs.of admin.  Contraindications: Act./hist.of ven. thromboembol. disords.,
   rule out malignancy in case of undiagnosed, persistent or recurrent   Contraindications: Sev.hepat.insuffic., pregn./ suspect.pregn.  known/suspect.sex-ster. sensit. malign., pres./hist.of sev.hepat.dis.
   abnormal vaginal bleeding; discontinue treatment and evaluate cause   Side effects: V.common: Headache, naus., low. abdom.pain, bleed.  as long as liv.funct.val.not return.to norm., known.suspect. pregn.,
   of exacerbated migraine or recurrent/persistent/severe headaches   disturbs., fatig. Common: Dizzin., diarrh., vomit., breast tendern.,   undiagn.vag.bleed.
   following a new pattern.     bleed. pattern tempor.disturb.  Side effects: Irreg.bleed.patt., chang.bleed. intens./freq./durat.,
   DRUG INTERACTIONS: Lessened efficacy of contraceptive with   Warnings and special precautions: Not a replacem. for reg.   amenorrh., vag.infects., pharyngit., rhinit., UTI, hypersens., incr.ap-
   certain anti-epileptic agents, aminopenicillins, barbiturates,   contracept. method, does not prev. pregn.in every instance, inves-  pet. affect labilit., depress.mood, nervousn., decr.lib., anx., insomn.,
   herbal preparations including St John’s wort, rifampicin,  phenylb-  tig.poss.pregn. if menstruat.delay &gt;5 days/abnorm.bleed.at expect.   headache, dizzin., migrain., somnol., hot flush., abdom.pain, naus.,
   utazone, tetracycline, neomycin, chloramphenicol, sulphonamides,   menstruat.date/any other reas.to suspect. pregn., consid.ectop.pregn.  flatul., vomit., constipat., diarrh., acne, alopec., hypertrichos., rash,
   nitrofurantoin, meprobamate, phenacetin, pyrazole, chlorpromazine,     esp.in pres.of abdom./ pelv. pain/ collapse/ectop.pregn.hist./fallop.  prurit., back/musculoskelet.pain, arthralg., myalg., dysur., breast ten-
   dihydroergotamine sedatives and antarthritic drugs; plasma levels of   tube surg.or pelv.inflamm.dis., rep.use within one menstrual cycle not   dern./pain/enlarg,, irreg. menstruat., dysmenorrh., ovar.cyst, genit.
   oestrogen possibly increased with concomitant paracetamol, ascorbic   advis., sev.malabsorpt.syndr., precaut. against STD’s not replac., tfd.  discharge /prurit., vulvovag.discomf., galactorrh., impl.site pain/re-
   acid, CYP3A4-inhibitors (including itraconazole, ketoconazole, vori-  via milk to nurs. inft., continuat. of reg.hormn.contracept.not C/I, not   act., fatig., influenz.like illn., pain, pyrex., oed., incr. decr.weight,
   conazole and fluconazole), grapefruit juice and HMG-CoA reductase   recomm.in childr., limit.data in women und.16 yrs.  incr.BP., seborrh., urticar., angioed., aggravat.of angioed.&/ heredit.
   inhibitors (including atorvastatin and rosuvastatin); plasma levels   Interactions: Metabol.enhanc.by liv.enzyme induc., effic.reduc.by   angioed., insert./remov.of impl.may cause bruis., loc. irrit., scarr., fi-
   of co-administered cyclosporine, omeprazole, prednisolone and   barbit./phenytoin/ carbamazep./ Hypericum perforatum/rifampicin/   bros./infect.at impl.site,
   theophylline may be increased; plasma levels of co-administered   ritonavir/ rifabutin/griseofulvin/ampicill./other antibiot./ TB meds.&   paraesthes. /paraesthes.-like events, expuls./ migrat. of implant.,
   paracetamol, lamotrigine, clofibric acid, morphine and salicylic acid   cyclospor., cyclospor. metabol. poss.inhibit., oral antidiabet.& insul.   follic.dev.beyond norm.siz.
   may be decreased; co-administration of HIV protease inhibitors   requirem. poss.chang., poss.cyclospor.toxicit.,  Special precautions: Excl.pregn.bef.use, period. med. assess.ad-
   and non-nucleoside reverse transcriptase inhibitors may result   vis. with spec.ref.to BP., poss.incr. risk of breast Ca., rem.in event of
   in significant changes (increase or decrease) in plasma levels of   EVRA, Janssen Pharmaceutica  pregn./confirm. thrombos./ in case of long-term immobil.due to surg./
   oestrogen and progestin; action of benzodiazepines are increased by   Norelgestromin 6 mg, ethinylestradiol 600 µg/ 20 cm  patch.  ill., ass.risk fact.known to incr.ven./arter. thromboembol., poss.eff.on
                                                      2
   oral contraceptives; insulin and antidiabetic requirements may need   Indications: Pregn.prevent  periph.insul.resist.& gluc. tol.in diab.wom., excl.ectop.pregn.in case
   changes; seizure control may be reduced with co-administered lamo-  (S3) PATCH, 36/18.7/0491  of amenorrh./abdom.pain, rem.if sust.hypertens. dev./ if signif.BP
   trigine; possibly antagonises the effectiveness of oral anticoagulants,   704091-001: 3 patches, R159,37  incr.does not adeq.resp.to meds., ref. to special.if ac./chron.liv.funct.
   antihypertensive agents & hypoglycaemic agents; oestrogen therapy   Dosage: Apply to clean, dry intact hairless healthy skin devoid of any   dist.occ., women with tendenc.to chloasma should avoid expos. to
   may decrease the antidepressant response to  tricyclic antidepres-  topic.prod. Do not place on breasts/red irrit./cut skin. Rotate wkly.,   sun/UV radiat., more freq.replacem.may be req.in wom.with high.
   sants and increase their incidence of toxic side effects; oestrogens   may be kept in same anatomic.site. Press down firm.on applicat.   bod.weight., poss.jaund./ prurit.relat.to cholestas/gallstone format./
   may enhance the effects of glucocorticoids.  ensur.good adhes.check patch dly.  porphyr./ SLE/haemolyt.uraem.syndr./Sydenham’s chorea/ herpes
                                Re-apply patch if feasible or new patch if detach./ partly detach. If   gestation./otoscleros.-relat.hear. loss/ angioed., use non-hormon.
   QLAIRA (MDR Listing)         detach.for 24 hrs.or more addit. non-hormon.contracept. x7 days reqd.   contracept.dur. treatm. with hepat.enzym.-induc.meds.& for 28 days
   YAZ PLUS (MDR Listing)       One patch to be worn at a time.  aft.its discont., rem.of impl.and prescr.of non-hormon. contacept.
                                Apply 1  patch on first day of menses = start day. Patch change day
                                                              recomm.with long-term hepat. enzym.-induc.meds, does not prot.
                                    st
   BIPHASIL, (Aspen Pharmacare: Pharma) Pharmacare [P/S]  will be that same day, at any time on that sched.change day, every   against HIV infect. & other STDs.
   11 white tabs: levonorgestrel 50 µg, ethinyl oestradiol 50 µg. 10   week (ie. days 8, 15, 22 & then day 1 of next cycle.). Sngl. patch is   Drug interactions: Meds.induc.cytochrome P450 can incr.sex horm.
   orange tabs: levonorgestrel 125 µg, ethinyl oestradiol 50 µg. 7 red   worn for one full wk.(ie.7 days).  clear, incr.plasm.lev.with hepat. enzym.inhibit.such as CYP3A4, poss.
   placebo tabs.                Fourth wk. start.day 22 is a patch-free wk. Max. patch-free period   interfer.with metab.of other meds.e.g.cyclospor.tiss.& plasma conc.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page252.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page248.html">248</a>&nbsp;&nbsp;&nbsp;<a href="page249.html">249</a>&nbsp;&nbsp;&nbsp;<a href="page250.html">250</a>&nbsp;&nbsp;&nbsp;<a href="page251.html">251</a>&nbsp;&nbsp;&nbsp;<a href="page252.html">252</a>&nbsp;&nbsp;&nbsp;<a href="page253.html">253</a>&nbsp;&nbsp;&nbsp;<a href="page254.html">254</a>&nbsp;&nbsp;&nbsp;<a href="page255.html">255</a>&nbsp;&nbsp;&nbsp;<a href="page256.html">256</a>&nbsp;&nbsp;&nbsp;<a href="page257.html">257</a>&nbsp;&nbsp;&nbsp;<a href="page258.html">258</a>
             </td>
             <td width="35%"><a href="page254.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page254.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
